Biodesix announces pricing of oversubscribed and upsized underwritten offering of common stock and concurrent private placement

Louisville, colo.--(business wire)--biodesix, inc. (nasdaq: bdsx), a leading diagnostic solutions company with a focus in lung disease, today announced the pricing of its underwritten offering of 17,391,832 shares of its common stock at a price to the public of $1.15 per share. in addition, biodesix has entered into securities purchase agreements for a concurrent private placement of 760,857 shares of its series a non-voting convertible preferred stock at a price of $46.00 per share. subject to.
BDSX Ratings Summary
BDSX Quant Ranking